Skip to main
ELAN

ELAN Stock Forecast & Price Target

ELAN Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 25%
Buy 50%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

Elanco Animal Health demonstrates a robust market position, with its key product, Simparica Trio, maintaining a significant market share of over 50%, while the anticipated growth of Credelio Quattro from 12.8% to 16.8% by 2026 indicates strong competitive prospects. Additionally, notable year-over-year growth in the Advantage Family and Seresto products, reported at +33% and +28% respectively for the third quarter of 2025, underscores the company's effective product portfolio and healthy demand dynamics. These factors contribute to a fundamentally positive outlook for Elanco, suggesting resilience and growth potential in a competitive marketplace.

Bears say

Elanco Animal Health is facing potential near-term risks to earnings growth due to concerns surrounding its refinancing, particularly in light of Dentsply Sirona's recent high-interest bond offering. Despite achieving roughly 50% higher revenue, the company's EBITDA margin has declined by a couple of hundred basis points, indicating increased pressure on profitability. Additionally, the reported $28 million EBITDA outperformance in the second quarter may not be sufficient to offset these underlying financial challenges moving forward.

ELAN has been analyzed by 8 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 50% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Elanco Animal Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Elanco Animal Health Inc (ELAN) Forecast

Analysts have given ELAN a Buy based on their latest research and market trends.

According to 8 analysts, ELAN has a Buy consensus rating as of Jan 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23.62, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23.62, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Elanco Animal Health Inc (ELAN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.